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Abstract
A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications
was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted.
Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a
primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identiﬁed were change
in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and
accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external
replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were
tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour
disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies
in asthma should collect relevant ADR data as well as markers of efﬁcacy.
Introduction
Asthma is a common chronic condition, affecting over 230
million people worldwide [1–3]. The management of asthma
is guided by national and international evidence based
guidelines [4, 5], but there is inter-individual variability in
treatment response. This variation may be related to several
factors, including adherence, disease subtype and severity,
and environmental factors. In addition, a patient’s genotype
can affect outcomes of treatment in asthma [6–8]. The data
from these pharmacogenomic studies of asthma medication
efﬁcacy in children have progressed to the point where there
are now polymorphisms approaching clinical utility [9].
However, the overall effectiveness of a medicine is a
balance between the intended beneﬁts and potential risks.
Adverse drug reactions (ADRs) in asthma patients also need
to be considered. The medications used in asthma have a
well described set of ADRs associated with their use
(Table 1). In adult patients, ADRs are responsible for 6.5%
of all admissions, while 14.7% of adult inpatients experi-
ence an ADR [10, 11]. For paediatrics, 3% of all admissions
are related to ADRs [12], while over 17% of all paediatric
inpatients experience one or more ADR [13]. For asthmatic
patients, ADRs represent a signiﬁcant burden, reducing
their quality of life, and extract an economic cost on
healthcare systems worldwide [14, 15].
There is inter-individual variability in the type and
severity of ADR experienced by patients. Factors such as
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adherence, and disease subtype inﬂuence this, but genomic
factors are also important [16], with several genetic poly-
morphisms having been associated with severe ADRs
[17, 18]. Regulatory information to guide prescribers has
been updated to reﬂect these ﬁndings [19].
While the effect size in pharmacogenomic studies is often
larger than that seen in genetic epidemiology studies [20],
large cohorts are still required, and replication of ﬁndings is
essential if ﬁndings are to be adopted into clinical practice
[21]. International consortia, utilising the data from multiple
groups, have been developed to facilitate this process [22].
Within asthma, the pharmacogenomics in childhood asthma
(PiCA) consortia is well established, containing multiple
cohorts from studies around the world [23].
Our aim was to undertake a systematic review of phar-
macogenomic studies of ADRs related to asthma medications
across the entire population. In addition, in collaboration with
the PiCA consortia, a survey of research active groups in this
area was undertaken to establish the current prioritisation of
ADRs within asthma pharmacogenomic research, and to
determine the future research priorities.
Methodology
A systematic review of current evidence investigating
ADRs of asthma medications in pharmacogenomic studies
was undertaken. A protocol was submitted to the PICA
consortia before commencing.
Search
Electronic databases, Medline, Embase, and CINAHL, were
searched up till January 2018 to locate eligible studies,
using the terms “asthma” AND “pharmacogenomics” AND
“asthma medication”. A list of asthma medication for
inclusion in the search strategy was extracted from the
British National Formulary for Children (BNFC) with both
generic and brand names included (see Supplementary ﬁle
for full search strategy). No limit was placed on language,
publication date, or age of study population. References of
included studies were analysed to locate any additional
relevant studies of interest.
Study selection
Two reviewers (CK and DH), after removal of duplicates,
independently screened titles and abstracts for inclusion,
analysed full text for eligibility, and collectively completed
data extraction. Disagreements between the two reviewers
were discussed and resolved mutually.
Both randomised control trials (RCTs) and observational
studies were included. Studies were deemed eligible if
genome analysis had been undertaken, the researchers
examined a known drug used in asthma treatment and if
ADRs were stated. ADRs were included if stated as either a
primary or a secondary outcome of the study. An ADR was
classiﬁed according to the WHO deﬁnition [24]. A list of
the top ADRs for each class of asthma medication is shown
in Table 1 [25, 26]. Studies had to state the speciﬁc ADRs
related to asthma medications and were excluded if ADRs
were stated to be seen but no report produced with data. An
asthma exacerbation was classiﬁed as a failure of medica-
tion efﬁcacy rather than an ADR.
Quality assessment and analysis
Methodological quality assessment was undertaken of the
included studies: the Newcastle–Ottawa Quality Assessment
Table 1 List of adverse drug reactions for asthma drug classes (adapted from BNFC [24]).
Short acting B2 agonist Long acting B2 agonist Corticosteroids Leukotrienes Theophylline
Arrhythmias Arrhythmias Adrenal crisis Abdominal pain Arrhythmias
Fine tremor Arthralgia Adrenal suppression Abnormal dreams CNS stimulation
Headache Fine tremor Aggression/behavioural changes Aggressive behaviour Convulsions
Hyperglycaemia Headache Candidiasis Agitation/anxiety Diarrhoea
Hypersensitivity reactions Hyperglycaemia Cushing’s syndrome Dizziness Gastric irritation
Hypokalaemia Hypersensitivity reactions Hyperglycaemia Hallucinations Headache
Lactic acidosis Hypokalaemia Hypertension Headache Hypokalaemia
Muscle cramps Muscle cramps Reduced growth velocity Hyperkinesia Hypotension
Nausea Nausea Reduced mineral bone density Sleep disturbances Nausea and vomiting
Rash Rash Thirst Tachycardia
Sleep/behaviour disturbance Sleep/behaviour disturbance
Tachycardia Tachycardia
C. King et al.
Scale [27] was used for cohort and case–control studies, and
the Cochrane Risk of Bias tool for RCTs [28].
Results were extrapolated into a pre-determined data
table, and a qualitative analysis then conducted on the
extracted data, with each asthma medication then indivi-
dually reported.
PiCA survey
An online survey was undertaken of PiCA consortia
members to establish if this review had identiﬁed all pos-
sible pharmacogenomic studies analysing ADRs and
asthma. In addition, the survey collated responses regarding
the importance of capturing ADRs in future studies, and
which ADRs’ members felt should be investigated in the
future.
Results
There were 1409 results after removal of duplicates generated
from the search strategy, but of these, only ﬁve were eligible
for inclusion [29–31]. From the survey sent, two additional
studies were discovered [32, 33] (Fig. 1). Adverse events such
as decreased efﬁcacy or increased asthma exacerbations were
reported in some papers, but as pre-speciﬁed, these were not
included. Within the eligible studies, a three reported on
ADR’s as an end point of their studies.
In the included studies, four were RCTs [29, 30, 32, 33],
and one was a cohort study [31]. All included studies had a
low risk of bias (see Supplementary ﬁle). Two of the studies
were undertaken in the United Kingdom with the other three
having been carried out in the USA. The overall sample size
of the studies was 1457 participants, with the largest pro-
portion of participants being from a paediatric population.
The characteristics of the included studies are shown in
Table 2.
One study examined ADRs with inhaled short acting
beta-2 agonists (SABA) [29], one analysed long acting beta-
2 agonists (LABA) [30], three studies examined the use of
corticosteroids [31–33], while no studies have examined
ADRs occurring with either leukotriene receptor antagonists
(LTA) or theophylline. For the SABA and LABA studies, a
candidate gene approach was applied [29, 30], whereas in
the three corticosteroid studies, genome-wide association
studies (GWAS) were used [31–33].
When analysing the genes identiﬁed in the studies, the
candidate gene studies examined the SNP rs1042713, on the
beta-2 adrenergic receptor gene (ADRB2). In contrast, the
platelet derived growth gene (PDGFD), the rap guanine
nucleotide exchange factor 5 gene (RAPGEF5), the tubulin
folding cofactor D (TBCD), and the tubulin gamma 1 gene
(TUBG1) were all identiﬁed through GWAS. The ADR’s
associated with each SNP, and presence or absence of
replication datasets, is shown in Table 3.
Regarding the ADR’s in SABAs, one study [29],
examining 78 adults found that if participants had the
Fig. 1 Prisma ﬂowchart showing screening and inclusion of studies.
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homozygous Arg16/Arg16 allele then the performance was
lower when on albuterol compared with the placebo, with
the peak expiratory ﬂow rate being 23 L/min better when
albuterol was stopped. However, when this was replaced
with ipratropium bromide, an anti-muscarinic, this group of
participants had higher peak ﬂow rates than when on
albuterol or placebo.
For LABAs, one study [30] that had examined 22 adult
participants found that participants with the homozygous
Gly16/Gly16 genotypes had maximum FEV1, maximum
FEF25–75, 6 h FEV1, and 6 h FEF25–75 values lower compared
with the Arg16/Arg16 genotype when given formoterol.
With inhaled corticosteroids, one study [31], examining
407 children from the PASS (Pharmacogenetics of Adrenal
Suppression with Inhaled Steroids) study aged 5–18 years
found that the SNP rs591118, located in the vicinity of the
PDGFD gene, was associated with a higher risk of adrenal
suppression (odds ratio in the paediatric asthma replication
cohort 3.86, 95% CI 1.19–12.50).
For oral corticosteroids, two studies [32, 33] examined
children aged 5–12 years, from the CAMP (Childhood
Asthma Management Program) trial, and the effect of pre-
dnisone on bone mineral density (BMD) z scores and bone
mineral accretion (BMA). For decreases in BMD-z scores
one SNP was identiﬁed, rs6461639, and in the acute lym-
phoblastic leukaemia (ALL) replication cohort it was sig-
niﬁcant (p value= 0.016) [33]. With the other study [32],
two associated SNPs were found to worsen BMA with
increased prednisone dosage, rs989633 and rs207439.
Internal replication was undertaken in two of the studies,
both that examined corticosteroids [31, 33]. However,
additional publications attempting external replication of
these polymorphisms have not been identiﬁed.
Survey results
There were 20 PiCA members who participated in the
survey, representing 15 institutes from the consortia in 67%
of participating countries. Ninety ﬁve percent identiﬁed
ADRs as an area that should be captured in pharmacoge-
nomic studies, and 80% of respondents agreed that only a
small percentage of studies currently assessed this area. The
survey respondents undertook a prioritisation exercise to
establish the ADRs for each asthma medication they believe
should be subject to further pharmacogenomics research.
The results of this prioritisation exercise are shown in
Table 4 (ranked in order of highest priority to lowest). The
most important ADRs by consensus for each drug class
varied; for beta-2 agonists (SABA or LABA) it was
tachycardia, for corticosteroids it was both adrenal sup-
pression/crisis and reduced growth, for LTAs it was sleep/
behaviour disturbances, and for theophylline it was nausea
and vomiting. Not all participants completed the survey for
Table 4 ADR's from survey and
number of people who
prioritised each.
Beta-2 agonists Corticosteroids Leukotriene receptor
antagonists
Theophylline
Tachycardia (14) Adrenal suppression
crisis (11)
Sleep/behaviour
disturbances (12)
Nausea and
vomiting (9)
Arrhythmias (9) Reduced growth (11) Headache (7) Arrhythmias (7)
Fine Tremor (8) Candidiasis (4) Nausea and vomiting (5) Headache (5)
Hypokalaemia (6) Hyperglycaemia (4) Tachycardia (3) Tachycardia (4)
Tachypnoea (4) Sleep/behaviour
disturbances (3)
Hypersensitivity
reactions (2)
Sleep/behaviour
disturbances (3)
Lactic acidosis (3) Bone complications (3) Rash (2) Hypokalaemia (2)
Nausea and
vomiting (3)
Fine tremor (2) Fine tremor (1) Tachypnoea (2)
Headache (2) Headache (2) Abdominal pain (1) Fine tremor (2)
Asthma
exacerbation (2)
Nausea and
vomiting (2)
Hypokalaemia (1) Lactic acidosis (1)
Hyperglycaemia (2) Rash (1) Lactic acidosis (1) Hyperglycaemia (1)
Sleep/behaviour
disturbances (1)
Asthma
exacerbation (1)
Candidiasis (1) Rash (1)
Tachyphylaxis (1) Dizziness (1) CNS problems (1)
Agitation/anxiety (1)
Infection/
immunosuppression (1)
Asthma exacerbation (1)
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ADRs of each drug. For theophylline, 39% reported that the
drug was no longer used in current treatment steps.
Discussion
This is the ﬁrst systematic review that considers the harms
of anti-asthma medications and their relationship to an
individual’s genetic variability. This systematic review has
identiﬁed six different ADRs that have pharmacogenomic
associations, but these are a small subset of the overall
pharmacogenomic research in asthma. In addition, there is a
lack of replication cohorts within the current evidence with
only two studies including internal replication cohorts in
their research. In both studies, these replication cohorts
successfully demonstrated the associations with individual
polymorphisms identiﬁed in the discovery cohort.
The survey of PiCA consortia members supported future
pharmacogenomic research into ADRs in asthma, and
prioritised ADRs for each anti-asthma medication class. For
most of the prioritised ADRs, we have not been able to
identify any published pharmacogenomic data. In addition,
we note that while ADRs associated SABA/LABA medi-
cations were not the ones prioritised in the survey. How-
ever, for corticosteroids the ADRs identiﬁed in publications
did correlate well with the ADRs prioritised in the survey.
Asthma is a disease that is particularly suitable for perso-
nalisation of therapy to either select efﬁcacious medicines
or avoid harms, as there are several possible medications,
and so alternate drug selections are possible.
A minority of participants in the survey commented
about whether frequency of asthma exacerbations is an
ADR for beta-2 agonists, corticosteroids, and LTA’s. They
are included in the results of the survey. The protocol for the
systematic review excluded these a priori as they were
considered a failure of treatment, not a worsening of dis-
ease. However, we note the core outcome set for childhood
asthma does include risk of hospitalisation secondary to
asthma exacerbations. Reviewing the literature, asthma
exacerbations have been deﬁned as adverse events rather
than ADRs in previous pharmacogenomic studies
[6, 34, 35]. A study, examining children with asthma who
were on ICS plus LABA identiﬁed an increase of asthma
exacerbations of 52% in those homozygous for the Arg16/
Arg16 allele of ADRB2 [34]. However, it needs to be
determined if asthma exacerbations should be classiﬁed as
an ADR in future studies or is to do with efﬁcacy instead.
Desensitisation to these medications may also occur. This
was considered for the included studies examining lung
function, but they were included as either the lung function
was worse than placebo [29] or there was no placebo to
compare against [30].
A limitation of this study is that, as for any systematic
review, the quality of the data produced is dependent on the
quality of existing publications, and there were a paucity of
eligible papers covering a range of drugs and ADRs. These
studies all had relatively small sample sizes, and the
diversity of ADRs identiﬁed precluded meta-analysis.
However, the identiﬁcation and prioritisation of ADRs by
members of the PiCA consortia is a positive indicator that
future pharmacogenomic studies may include more ADRs
as well as markers of efﬁcacy.
Conclusion
There are few pharmacogenomic studies of ADRs in asthma
that have been undertaken. None of the studies that have
been undertaken have been externally replicated, although
one has only just been published. Future pharmacogenomic
studies in asthma should collect relevant ADR data as well
as markers of efﬁcacy. Drug speciﬁc ADR priorities have
been established to guide researchers.
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